+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study



Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study



Haematologica 86(7): 749-752



Background and Objectives: Cytomegalovirus (CMV) infection continues to be a major complication of bone marrow transplants (BMTs). Administration of leukoreduced unscreened cellular blood products at the bedside has been shown to be effective in preventing CMV transmission via transfusions in CMV-seronegative bone marrow transplant recipients who receive their transplants from CMV-seronegative donors. The aim of this study was to determine whether CMV infection occurred in CMV-seronegative BMT patients who received CMV-seronegative donor marrows and CMV untested blood products leukodepleted at the bedside. Design and Methods: We collected data over a 2-year period from patients undergoing allogeneic transplantation who received leukoreduced cellular blood components that were not screened for CMV. All CMV-seropositive patients and donors were excluded from the study. The CMV status of both the donors and the patients was determined before the transplantations. CMV cultures of urine, blood buffy coat, bone marrow samples and bronchial washings were performed if necessary in patients. Results: Thirty-six CMV-seronegative patient-donor pairs were included in the study. Five patients (13.89%) were serologically reactive, but their CMV cultures were negative and they did not show signs or symptoms of CMV infection. These patients received intravenous immunoglobulin and thus could have acquired anti-CMV passively. Interpretation and Conclusions: The confidence interval in this study is 0/36 incidence of CMV infection. Our present findings support those of prior studies showing the effectiveness of filtered unscreened blood components as an alternative transfusion support for CMV-seronegative marrow transplant recipients. Studies in larger number of patients are warranted.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010231012

Download citation: RISBibTeXText

PMID: 11454531


Related references

Leukoreduction does not affect cytomegalovirus disease in allogeneic bone marrow transplant recipients. Transfusion 35(10 Suppl. ): 63S, 1995

Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Bone Marrow Transplantation 36(6): 499-501, 2005

Prevention of cytomegalovirus infection in allogeneic bone marrow transplant recipients by using cytomegalovirus negative blood products. Bone: 67-68, 1986

The clinical utility of cytomegalovirus antigenemia in allogeneic bone marrow transplant recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 232, 1997

Cytokine mediators in cytomegalovirus pneumonitis in allogeneic bone marrow transplant recipients. Clinical Research 41(3): 592A, 1993

Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. British Journal of Haematology 87(1): 144-147, 1994

Detection of human cytomegalovirus DNA from allogeneic bone marrow transplant recipients with interstitial pneumonitis. American Journal of the Medical Sciences 312(1): 1-7, 1996

Prophylactic application of an anti-cytomegalovirus hyperimmunoglobulin in allogeneic bone marrow transplant recipients. Haematology and Blood Transfusion 30: 541-544, 1987

Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplantation 17(4): 589-593, 1996

Laboratory assays for cytomegalovirus as predictors of survival in allogeneic bone marrow transplant recipients. Abstracts of the General Meeting of the American Society for Microbiology 97: 533, 1997

Neutralizing antibody response against human cytomegalovirus in allogeneic bone marrow-transplant recipients. Journal of Infectious Diseases 180(5): 1747-1748, 1999

A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplantation 28(5): 485-490, 2001

Late Cytomegalovirus Pneumonia in Adult Allogeneic Blood and Marrow Transplant Recipients. Clinical Infectious Diseases 28(3): 618-623, 1999

Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clinical Infectious Diseases 28(3): 618-623, 1999

Cytomegalovirus and adenovirus infections and diseases among 75 paediatric unrelated allogeneic bone marrow transplant recipients. Journal of Medical Virology 72(2): 257-262, 2004